<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03050047</url>
  </required_header>
  <id_info>
    <org_study_id>BCD-100-1</org_study_id>
    <nct_id>NCT03050047</nct_id>
  </id_info>
  <brief_title>A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study of BCD-100 in Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of BCD-100 (JSC BIOCAD, Russia) in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biocad</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biocad</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study of Pharmacokinetics,&#xD;
      Pharmacodynamics, Safety, and Immunogenicity of BCD-100 (JSC BIOCAD, Russia) in Patients with&#xD;
      Advanced Solid Tumors&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">August 30, 2016</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Actual">July 1, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR (CR + PR)</measure>
    <time_frame>85 days</time_frame>
    <description>Pilot efficacy assessment is not the primary objective of this study and will be conducted by surrogate endpoints describing the direct antitumor effect of the drug.&#xD;
• ORR (CR + PR) after 85 days of therapy with BCD-100.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Melanoma</condition>
  <condition>Lung Cancer</condition>
  <condition>Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>BCD-100 0.3 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who receive BCD-100 in a dose of 0.3 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCD-100 1 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who receive BCD-100 in a dose of 1 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCD-100 3 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who receive BCD-100 in a dose of 3 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCD-100 10 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who receive BCD-100 in a dose of 10 mg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BCD-100</intervention_name>
    <description>Anti-PD1 monoclonal antibody</description>
    <arm_group_label>BCD-100 0.3 mg/kg</arm_group_label>
    <arm_group_label>BCD-100 1 mg/kg</arm_group_label>
    <arm_group_label>BCD-100 10 mg/kg</arm_group_label>
    <arm_group_label>BCD-100 3 mg/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient provides a written informed consent and is able to follow the requirements of&#xD;
             the Protocol;&#xD;
&#xD;
          2. Age ≥ 18 years&#xD;
&#xD;
          3. Histologically confirmed cancer (well-documented test results; preferably, block&#xD;
             specimens available):&#xD;
&#xD;
               -  unresectable (stage III/IV) or metastatic (stage IV) melanoma (the drug will be&#xD;
                  used as the first of subsequent therapy lines);&#xD;
&#xD;
               -  Locally advanced or metastatic NSCLC (squamous cell carcinoma/adenocarcinoma),&#xD;
                  progressive after at least the first-line therapy (the drug will be used as a&#xD;
                  second or subsequent therapy lines);&#xD;
&#xD;
               -  Metastatic clear cell renal carcinoma, progressive after at least the first-line&#xD;
                  therapy (the drug will be used as a second or subsequent therapy lines);&#xD;
&#xD;
             In addition, by investigator's decision, patients with the following malignancies can&#xD;
             also be enrolled in the study :&#xD;
&#xD;
               -  Pleural mesothelioma progressive after at least one therapy line (the drug will&#xD;
                  be used as a second or subsequent therapy lines);&#xD;
&#xD;
               -  Metastatic bladder cancer progressive after at least one therapy line (the drug&#xD;
                  will be used as a second or subsequent therapy lines);&#xD;
&#xD;
               -  Triple negative breast cancer (ER-, PR-, HER2-) progressive after at least the&#xD;
                  first-line therapy (the drug will be used as a second or subsequent therapy&#xD;
                  lines);&#xD;
&#xD;
          4. ECOG score of 0 to 2;&#xD;
&#xD;
          5. Measurable disease (at least one lesion) according to RECIST v. 1.1 ;&#xD;
&#xD;
          6. Resolved toxicity events from the previous therapy or adverse consequences of surgical&#xD;
             interventions to ≤ grade 1 CTCAE v. 4.03, except for chronic/irreversible adverse&#xD;
             events not affecting the safety of the study therapy (e.g. alopecia);&#xD;
&#xD;
          7. No severe pathology of organs or systems;&#xD;
&#xD;
          8. Life expectancy of at least 12 weeks from the screening;&#xD;
&#xD;
          9. Patients of childbearing potential enrolled in the study must agree to use reliable&#xD;
             contraception methods throughout the study period, beginning 2 weeks before the&#xD;
             inclusion in the study and up to 8 weeks after the last dose of BCD-100.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Severe concomitant illnesses or life-threatening consequences (including&#xD;
             pleural/pericardial/peritoneal effusion that requires medical intervention , pulmonary&#xD;
             lymphangitis, or involvement of &gt;50% renal parenchyma);&#xD;
&#xD;
          2. Brain metastases, progressive or associated with clinical symptoms (e.g. cerebral&#xD;
             edema or spinal cord compression). Exclusions: metastases that do not progress and do&#xD;
             not require steroids and/or anticonvulsants within at least 4 weeks before&#xD;
             randomization ;&#xD;
&#xD;
          3. Severe cardiovascular disorders within 6 months before screening;&#xD;
&#xD;
          4. Autoimmune diseases;&#xD;
&#xD;
          5. Conditions requiring steroids or any other immunosuppressants;&#xD;
&#xD;
          6. Blood disorders: ANC ≤1,500/mm3; platelets ≤100,000/mm3; or Hb ≤90 g/L;&#xD;
&#xD;
          7. Renal function impairment: creatinine ≥1.5 × ULN;&#xD;
&#xD;
          8. Hepatic function impairment: bilirubin ≥1.5 × ULN; AST and ALT ≥2.5 × ULN (5 × ULN for&#xD;
             patients with liver metastases), AlkPh ≥ 5 × ULN;&#xD;
&#xD;
          9. Prior anticancer treatment within 28 days before starting the study drug (surgery,&#xD;
             radiation therapy , or chemotherapy);&#xD;
&#xD;
         10. Known history of more than 6 lines of systemic anticancer chemotherapy (including&#xD;
             neoadjuvant and adjuvant CTs);&#xD;
&#xD;
         11. Prior treatment with anti-PD1/PDL1 agents or CTLA4 inhibitors;&#xD;
&#xD;
         12. Concurrent malignancy except for radically resected cervical carcinoma in situ or&#xD;
             radically resected basal cell/squamous cell carcinoma;&#xD;
&#xD;
         13. Conditions limiting patient's ability to follow the Protocol requirements (dementia,&#xD;
             neurological or psychiatric disorders, drug or alcohol abuse, etc.);&#xD;
&#xD;
         14. Simultaneous participation in any other clinical trial; participation in other&#xD;
             clinical trials within 30 days before inclusion in the present study; previous&#xD;
             participation in the present study.&#xD;
&#xD;
         15. Acute infections or active chronic infections;&#xD;
&#xD;
         16. Documented HIV infection;&#xD;
&#xD;
         17. Positive screening results for Hbs-antigen, hepatitis B core antibodies (anti-HBc Ab)&#xD;
             and/or hepatitis C antibodies ;&#xD;
&#xD;
         18. Positive results of microprecipitation reaction together with positive TPHA assay&#xD;
             results at the screening;&#xD;
&#xD;
         19. Body weight &gt; 95 kg.&#xD;
&#xD;
         20. Intravenous administration of the drug is impossible;&#xD;
&#xD;
         21. Intravenous administration of contrast agents is impossible;&#xD;
&#xD;
         22. Hypersensitivity to any component of BCD-100.&#xD;
&#xD;
         23. Known history of hypersensitivity to monoclonal antibodies;&#xD;
&#xD;
         24. Pregnancy or breastfeeding;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>&quot;Russian Cancer Research Center named after N.N. Blokhin &quot;of the Ministry of Health of the Russian Federation</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LLC BioEk</name>
      <address>
        <city>Saint-Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State budgetary health care institution &quot;St. Petersburg Clinical Scientific and Practical Center of Specialized Medical Assistance (Oncological)&quot;</name>
      <address>
        <city>Sankt Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>N.N.Petrov Oncology Research Center</name>
      <address>
        <city>St.Petersburg</city>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>February 8, 2017</study_first_submitted>
  <study_first_submitted_qc>February 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 10, 2017</study_first_posted>
  <last_update_submitted>August 29, 2018</last_update_submitted>
  <last_update_submitted_qc>August 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

